Roche shows steady earnings growth and resilience in 2026 amid market volatility.

Roche, the Swiss pharmaceutical and diagnostics company, continues to deliver steady earnings growth and strong margins in 2026 despite a challenging market environment. The company reported 6% sales growth at constant exchange rates in Q1 2026 and maintains its outlook for mid single-digit sales growth and high single-digit core earnings growth for the year. Roche's diversified portfolio in oncology, diagnostics, and specialty medicines, along with its global footprint, provides stability and resilience against economic fluctuations. This makes Roche a reliable defensive investment with long-term growth potential in healthcare demand driven by aging populations and innovation.